Table 1.
Clinical Patients’ Characteristics
| Variable | Mild Course | Severe Course (n = 19) | Total Group (n = 30) | |
|---|---|---|---|---|
| No Hospital Admission Indicated (n = 11) | Hospital Admission Indicated (n = 15) | Fatal (n = 4) | ||
| Sex, n (%) | ||||
| Male | 4 (25%) | 9 (56%) | 3 (19%) | 16 (53%) |
| Female | 7 (50%) | 6 (43%) | 1 (7%) | 14 (47%) |
| Median age in years (interquartile range) | 55 (38-67) | 59 (55-65) | 71 (52-77.25) | 60 (50.75-70.25) |
| Risk factors, n (%) | ||||
| Smoking | 5 (50%) | 3 (30%) | 2 (20%) | 10 (33%) |
| Cardiovascular diseasea | 3 (33%) | 4 (44%) | 2 (22%) | 9 (30%) |
| BMIb ≥30 | 4 (57%) | 3 (43%) | 0 (0%) | 7 (23%) |
| COPDc | 0 (0%) | 1 (100%) | 0 (0%) | 1 (3%) |
| Diabetes mellitus | 0 (0%) | 1 (100%) | 0 (0%) | 1 (3%) |
| Prior/other malignancy | 1 (20%) | 2 (40%) | 2 (40%) | 5 (17%) |
| Use of dexamethasone at moment of COVID-19 diagnosis, n (%) | ||||
| No | 7 (47%) | 6 (40%) | 2 (13%) | 15 (50%) |
| Yes | 4 (27%) | 9 (60%) | 2 (13%) | 15 (50%) |
| Brain tumor type, n (%) | ||||
| Glioblastoma | 6 (33%) | 9 (50%) | 3 (17%) | 18 (60%) |
| Astrocytoma (WHO grade II/III) | 4 (67%) | 1 (17%) | 1 (17%) | 6 (20%) |
| Oligodendroglioma (WHO grade II/III) | 1 (33%) | 2 (67%) | 0 (%) | 3 (10%) |
| Ependymoma | 0 (0%) | 1 (100%) | 0 (%) | 1 (3%) |
| PCNSL | 0 (0%) | 2 (100%) | 0 (%) | 2 (7%) |
| Cancer treatment, n (%) | ||||
| Received treatment <90 days before COVID-19 diagnosisd | 7 (37%) | 9 (47%) | 3 (16%) | 19 (63%)d |
| Surgery | 0 (0%) | 0 (0%) | 3 (100%) | 3 (16%)e |
| Chemoradiation with temozolomide | 5 (83%) | 1 (17%) | 0 (0%) | 6 (32%)e |
| Radiotherapy | 0 (0%) | 5 (100%) | 0 (0%) | 5 (26%)e |
| Chemotherapy | ||||
| Temozolomide | 0 (0%) | 1 (100%) | 0 (0%) | 1 (5%)e |
| High-dose methotrexate | 0 (0%) | 2 (100%) | 0 (0%) | 2 (11%)e |
| PCVf | 1 (100%) | 0 (0%) | 0 (0%) | 1 (5%)e |
| Otherg | 1 (100%) | 0 (0%) | 0 (0%) | 1 (5%)e |
aIncluding patients with hypertension.
bBody mass index.
cChronic obstructive pulmonary disease.
dFor the patients who had active treatment (ie, oncological treatment <90 days before diagnosis of COVID-19), the last administered oncological treatment is shown.
ePercentage of patients who received active treatment, that is, any oncological treatment for primary brain tumor within 90 days before diagnosis of COVID-19.
fProcarbazine, lomustine, and vincristine regimen.
gImmunotherapy in form of nivolumab, as part of the trial.